Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20789345 | 0.84 | HSD11B1 (0.41) | HSD11B1HSD11B2 | |
| SCHEMBL20789206 | 0.72 | IDO1 (0.39) | HSD11B1HSD11B2 | |
| SCHEMBL25638989 | 0.72 | HSD11B1 (0.40) | HSD11B1HSD11B2EPHX2KMT2A | |
| SCHEMBL23879650 | 0.71 | HSD11B1 (0.47) | HSD11B1HSD11B2KMT2A | |
| SCHEMBL20789220 | 0.69 | IDO1 (0.41) | SMN1; SMN2 | |
| SCHEMBL20789363 | 0.68 | IDO1 (0.40) | HSD11B1SMN1; SMN2 | |
| SCHEMBL25638991 | 0.68 | HSD11B1 (0.41) | HSD11B1HSD11B2KMT2ASMN1; SMN2 | |
| SCHEMBL26363428 | 0.68 | CRBN (0.36) | EPHX2 | |
| SCHEMBL11030937 | 0.67 | — | — | |
| SCHEMBL2824301 | 0.67 | HSD11B1 (0.41) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590122-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190077799-A1 | RAD51 Inhibitors | CYTEIR THERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590122-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | HSD11B1 1900/4885HSD11B2 2091/4885EPHX2 3010/4885 |
| US-20190077799-A1 | RAD51 Inhibitors | RAD51, MRE11, RAD54L | HSD11B1 1900/4885HSD11B2 2091/4885EPHX2 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.